Autologous Peptide-coupled Red Blood Cells therapy(Cellerys)

N/A

Report date: 2024/05/31 17:01:38

Base Information

Drug NameAutologous Peptide-coupled Red Blood Cells therapy(Cellerys)

Drug Alias NameCLS-12311CLS12311

ClassificationCell and gene therapy > Cell therapy > Somatic cell > Erythrocyte therapyCell and gene therapy > Cell therapy > Peptide-cell conjugateCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionCell replacements

TargetsUpdating

Therapy Area/IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaItalyGermany +[4]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCellerys AG Novartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag Cellerys AG

Inactive CompaniesN/A

Active IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A